Navigation Links
The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
Date:6/28/2011

1-year results from a randomized, placebo-controlled trial," by Sherry, et al.(1) and provides the results of per protocol as well as exploratory, post hoc analyses.  The findings suggest that "future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in beta-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children."

The article indicates that teplizumab treatment may preserve beta cell function as measured by C-peptide, allowing less insulin use to achieve the same glycemic control as patients receiving placebo. A greater proportion of patients in the teplizumab groups were able to discontinue or use very low doses of insulin compared to the placebo group.  A reduced insulin requirement while maintaining glycemic control appears to support teplizumab having a biological effect.

In the safety analyses, the proportion of patients who had adverse events and serious adverse events was similar across the four study groups.  Rash was the most common clinical adverse event reported more frequently with teplizumab than placebo. Mild cytokine release syndrome was infrequent but greater in treatment groups compared to placebo. The safety profile was characterized by transient increases in some liver function test results and transient decreases in white cells that prevent infections. However, no increase in overall infections was seen.

"We are very pleased to have teplizumab Phase 3 data published in this prestigious journal," stated Dr. Scott Koenig, President and CEO of MacroGenics.  "Although the Protege study missed its primary endpoint, the data appear to indicate that teplizumab has a desired biological effect in certain subpopulations with a potentially meaningful therapeutic benefit for patients with recent-onset type 1 diabetes.  These groups in
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
4. CHAMPION Study Published in The Lancet
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
10. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  Thoratec Corporation (NASDAQ: THOR ), a ... and restore failing hearts, announced today that Marta Antonucci ... President, International. This new Europe ... of North America , including ... Latin America , and reports directly to the ...
(Date:5/1/2015)...  Legendary actor and director Danny Glover ... designed to educate and encourage patients with neurologic conditions, ... (PBA) and to speak with their physician. The campaign ... ability to cry and laugh on cue and how ... people living with PBA episodes. While PBA ...
(Date:5/1/2015)... , May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... Timothy E. Morris , chief financial officer  will be ... events are as follows: Mizuho Third Annual ...  The Omni Berkshire Place, New York ...
Breaking Medicine Technology:Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2
... May 10, 2011 Cobalis Corp. (CLSC.PK) announced today ... PreHistin® Allergy Defense Formula , on major national cable ... commercials, featuring leading US allergist Dr. Paul H. Ratner, ... of allergies, giving seasonal and year-round sufferers the first ...
... is being released by SafeMinds ( www.SafeMinds.org ): ... publicly denied a vaccine-autism link, while at the same ... awarding damages for vaccine injury to children with brain ... verifiable government data, breaks ground in the controversial vaccine-autism ...
Cached Medicine Technology:Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula 2Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula 383 Cases of Autism Associated with Childhood Vaccine Injury Compensated in Federal Vaccine Court 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 Peacock Alley ... our mothers. He said, “My mother was the most beautiful ... wrap her in lovely, feminine prints and textures ... Look no further than the Eloise Robe to get you ... with its cap sleeve and tapered waist. It is available ...
(Date:5/3/2015)... 2015 AvePoint, the ... and devices, today announced it is a Platinum ... (IAPP) Asia Privacy Forum, taking place May 5-6, ... event, AvePoint will showcase its compliance, risk, and ... , Visit AvePoint for New Solutions , ...
(Date:5/3/2015)... Leading international program provider, Child Family ... the 2015 Harris Wofford Global Service Fellowships. CFHI Global ... deserving recipients of the award named after former US ... The two recipients were chosen for their strong commitment ... , CFHI is one of seven organizations participating in ...
(Date:5/3/2015)... 03, 2015 Looking for a ... directly impact your career? The Master of International ... leaders in multinational companies and for professionals seeking ... changing global landscape, differences in culture, religion, government, ... EMIB program develops the global competence and confidence ...
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
Breaking Medicine News(10 mins):Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3
... found most were as effective, despite editorials urging opposite ... used to treat cardiovascular disease are no better than ... Yet a number of editorials in medical journals, written ... generics for their designer counterparts. , "We found no ...
... ANN ARBOR, Mich.---Older people tend to feel about 13 years ... the findings of a study forthcoming in the Journals ... of 516 men and women age 70 and older who ... about age and their satisfaction with aging changed over a ...
... or animals by blocking certain bacteria from growing in their ... stopping infectious diseases such as West Nile virus and Malaria ... viruses. Research to be presented at the 57th American ... New Orleans, explains how vaccines and drugs may not only ...
... 2 TROY Group, Inc.,(Pink Sheets: TROY), a ... first digital printer for printing the federally,mandated security ... SecureRx,printer allows healthcare providers to significantly reduce the ... regulations,established by the Center for Medicare and Medicaid ...
... eOn Communications,Corporation(TM) (Nasdaq: EONC ), a leading ... a contract from the GSA for the,expansion of the ... Germany. Implementation commenced in November and is expected ... "This contract is a confirmation ...
... 2 The Sun Shower(TM) brand just got,better with the ... teas,and lattes. Each flavor contains Lifeguard(TM) Protection, a fortification,package ... half the,calories of the leading brands. , ... our new line of Sun Shower(TM) Super,Blends iced coffees, teas ...
Cached Medicine News:Health News:Generic Heart Drugs as Good as Brand-Name Counterparts 2Health News:Generic Heart Drugs as Good as Brand-Name Counterparts 3Health News:Old as you want to be: Study finds most seniors feel younger 2Health News:Vaccine and drug research aimed at ticks and mosquitoes to prevent disease transmission 2Health News:TROY SecureRx Revolutionizes Prescription Printing 2Health News:TROY SecureRx Revolutionizes Prescription Printing 3Health News:TROY SecureRx Revolutionizes Prescription Printing 4Health News:eOn Communications Announces GSA Contract 2Health News:eOn Communications Announces GSA Contract 3Health News:New Sun Shower(TM) Super Blends: Iced Coffees, Teas, Lattes With Half the Calories 2
Provides a combination of concentrated cold / hot and compression for the neck...
Provides extended cold therapy for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and speed recovery....
Provides a combination of concentrated cold / hot and compression for the shoulder...
Provides extended cold therapy to the shoulder area for acute, chronic, or post-surgical applications. The DuraKold products can help reduce pain, edema, and speed recovery....
Medicine Products: